REGN-COV2 Antibody Cocktail

Chemical Namecasirivimab and imdevimab
Dosage FormInjection (intravenous; 120 mg/mL casirivimab/120 mg/mL imdevimab)
Drug ClassMonoclonal antibodies
CompanyRegeneron Pharmaceuticals
Approval Year2020


  • For the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID19 and/or hospitalization.
Last updated on 11/24/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
REGN-COV2 Antibody Cocktail (Casirivimab and imdevimab) Prescribing Information2020Regeneron Pharmaceuticals, Inc. Tarrytown, NY